IE49988B1 - Analgesic mixture of nalbuphine and acetaminophen - Google Patents

Analgesic mixture of nalbuphine and acetaminophen

Info

Publication number: IE49988B1
Authority: IE; Ireland
Prior art keywords: nalbuphine; acetaminophen; composition; analgesic; tablets
Prior art date: 1979-05-18

Application number

IE1019/80A

Other languages

English (en)

Other versions

IE801019L (en

Original Assignee

Du Pont

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-05-18

Filing date

1980-05-16

Publication date

1986-01-22

1980-05-16 Application filed by Du Pont filed Critical Du Pont

1980-11-18 Publication of IE801019L publication Critical patent/IE801019L/xx

1986-01-22 Publication of IE49988B1 publication Critical patent/IE49988B1/en

Links

RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 79
229960005489 paracetamol Drugs 0.000 title claims abstract description 39
229960000805 nalbuphine Drugs 0.000 title claims abstract description 37
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 title claims abstract description 37
239000000203 mixture Substances 0.000 title claims abstract description 20
230000000202 analgesic effect Effects 0.000 title claims abstract description 17
238000000034 method Methods 0.000 claims description 7
230000036407 pain Effects 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 description 17
239000003814 drug Substances 0.000 description 14
229940079593 drug Drugs 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229920000881 Modified starch Polymers 0.000 description 7
239000004368 Modified starch Substances 0.000 description 7
235000019426 modified starch Nutrition 0.000 description 7
239000008213 purified water Substances 0.000 description 7
RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
235000021355 Stearic acid Nutrition 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
239000008117 stearic acid Substances 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
230000036592 analgesia Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
235000010234 sodium benzoate Nutrition 0.000 description 3
239000004299 sodium benzoate Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000003467 diminishing effect Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
-1 elixirs Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IE1019/80A 1979-05-18 1980-05-16 Analgesic mixture of nalbuphine and acetaminophen IE49988B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/040,281 US4237140A (en)	1979-05-18	1979-05-18	Analgesic mixture of nalbuphine and acetaminophen

Publications (2)

Publication Number	Publication Date
IE801019L IE801019L (en)	1980-11-18
IE49988B1 true IE49988B1 (en)	1986-01-22

Family

ID=21910135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE1019/80A IE49988B1 (en)	1979-05-18	1980-05-16	Analgesic mixture of nalbuphine and acetaminophen

Country Status (12)

Country	Link
US (1)	US4237140A (2)
EP (1)	EP0019282B1 (2)
JP (1)	JPS55154917A (2)
AU (1)	AU529764B2 (2)
CA (1)	CA1139671A (2)
DE (1)	DE3061597D1 (2)
HU (1)	HU178867B (2)
IE (1)	IE49988B1 (2)
IL (1)	IL60095A (2)
NZ (1)	NZ193695A (2)
PH (1)	PH15265A (2)
ZA (1)	ZA802916B (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4322427A (en) *	1981-04-16	1982-03-30	Bristol-Myers Company	Analgetic compositions and methods of use
US4366159A (en) *	1981-09-08	1982-12-28	Michael Richard Magruder	Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4407805A (en) *	1982-06-30	1983-10-04	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and zomepirac
US4407804A (en) *	1982-06-30	1983-10-04	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and indomethacin
US4404211A (en) *	1982-06-30	1983-09-13	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and flurbiprofen
US4404208A (en) *	1982-06-30	1983-09-13	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and tiflamizole
US4404209A (en) *	1982-06-30	1983-09-13	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and sulindac
US4404210A (en) *	1982-06-30	1983-09-13	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and ibuprofen
US4402962A (en) *	1982-06-30	1983-09-06	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole
AU565634B2 (en) *	1982-06-30	1987-09-24	E.I. Du Pont De Nemours And Company	Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
US4656177A (en) *	1982-07-22	1987-04-07	Analgesic Associates	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
ZA835324B (en) *	1982-07-22	1984-09-26	Abraham Sunshine	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4777174A (en) *	1982-07-22	1988-10-11	Analgesic Associates	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4722928A (en) *	1985-12-02	1988-02-02	E. I. Du Pont De Nemours And Company	N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
CA2095523C (en)	1991-09-06	2004-06-22	Robert B. Raffa	Composition comprising a tramadol material and acetaminophen and its use
US5558876A (en) *	1995-03-29	1996-09-24	Alcon Laboratories, Inc.	Topical ophthalmic acidic drug formulations
US6348216B1 (en) *	1996-06-10	2002-02-19	Knoll Pharmaceutical Company	Ibuprofen and narcotic analgesic compositions
US6361794B1 (en)	1996-06-12	2002-03-26	Basf Corporation	Method of making ibuprofen and narcotic analgesic composition
EP1041987B1 (en)	1997-12-22	2006-04-19	Euro-Celtique S.A.	Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
EP2092936B1 (en)	2000-02-08	2013-03-20	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
EP1387673B1 (en)	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Abuse-resistant controlled-release opioid dosage form
SI1416842T1 (sl)	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en)	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
IL160222A0 (en) *	2001-08-06	2004-07-25	Euro Celtique Sa	Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en)	2001-08-06	2003-08-21	Christopher Breder	Sequestered antagonist formulations
HUE032656T2 (en)	2002-04-05	2017-10-30	Euro Celtique Sa	Pharmaceutical composition containing oxicodone and naloxone
CN1703200B (zh)	2002-09-20	2012-02-29	奥尔制药公司	隔离亚单元和相关组合物及方法
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en)	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
HUE053838T2 (hu) *	2005-08-24	2021-07-28	Endo Pharmaceuticals Inc	Nyújtott felszabadulású nabulfin-készítmények
US8394812B2 (en)	2005-08-24	2013-03-12	Penwest Pharmaceuticals Co.	Sustained release formulations of nalbuphine
SI2719378T1 (sl)	2006-06-19	2016-11-30	Alpharma Pharmaceuticals Llc	Farmacevtski sestavki
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
SG174286A1 (en)	2009-03-10	2011-10-28	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2016525138A (ja)	2013-07-23	2016-08-22	ユーロ−セルティークエス．エイ．	疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
PL3639828T3 (pl)	2013-12-24	2022-05-02	Virginia Commonwealth University	Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
JOP20190094A1 (ar) *	2016-10-27	2019-04-25	Broad Inst Inc	مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2019070917A1 (en) *	2017-10-03	2019-04-11	The Schepens Eye Research Institute, Inc.	COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
EP3846815A4 (en) *	2018-09-03	2022-05-04	Jacob Biotech Ltd	PHARMACEUTICAL PREPARATIONS OF SEBACOYL-DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR PAIN MANAGEMENT

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL26896A (en) *	1966-01-19	1970-11-30	Endo Lab	14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US4029798A (en) *	1975-06-02	1977-06-14	Sumitomo Chemical Company, Limited	Analgetic composition
JPS5946205B2 (ja) *	1976-01-01	1984-11-10	科研製薬株式会社	ベンゾイル誘導体を有効成分とする消炎鎮痛剤

1979
- 1979-05-18 US US06/040,281 patent/US4237140A/en not_active Expired - Lifetime
1980
- 1980-05-13 AU AU58351/80A patent/AU529764B2/en not_active Ceased
- 1980-05-13 NZ NZ193695A patent/NZ193695A/en unknown
- 1980-05-15 CA CA000352011A patent/CA1139671A/en not_active Expired
- 1980-05-15 EP EP80102696A patent/EP0019282B1/en not_active Expired
- 1980-05-15 DE DE8080102696T patent/DE3061597D1/de not_active Expired
- 1980-05-16 HU HU80801223A patent/HU178867B/hu not_active IP Right Cessation
- 1980-05-16 IE IE1019/80A patent/IE49988B1/en not_active IP Right Cessation
- 1980-05-16 PH PH24035A patent/PH15265A/en unknown
- 1980-05-16 ZA ZA00802916A patent/ZA802916B/xx unknown
- 1980-05-16 IL IL60095A patent/IL60095A/xx unknown
- 1980-05-17 JP JP6469980A patent/JPS55154917A/ja active Granted

Also Published As

Publication number	Publication date
EP0019282A1 (en)	1980-11-26
CA1139671A (en)	1983-01-18
NZ193695A (en)	1984-05-31
IL60095A (en)	1982-12-31
US4237140A (en)	1980-12-02
JPS55154917A (en)	1980-12-02
AU5835180A (en)	1980-11-20
AU529764B2 (en)	1983-06-16
IE801019L (en)	1980-11-18
IL60095A0 (en)	1980-07-31
DE3061597D1 (en)	1983-02-17
ZA802916B (en)	1981-12-30
HU178867B (en)	1982-07-28
PH15265A (en)	1982-11-02
EP0019282B1 (en)	1983-01-12
JPH0144684B2 (2)	1989-09-29

Legal Events

Date	Code	Title	Description
1996-02-21	MM4A	Patent lapsed

Publication	Publication Date	Title
US4237140A (en)	1980-12-02	Analgesic mixture of nalbuphine and acetaminophen
ES2120451T7 (es)	2009-11-05	Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
EP0316434B2 (en)	1999-06-16	Cough/cold mixtures comprising non-sedating antihistamine drugs
Glare et al.	1993	Dose-ranging study of oxycodone for chronic pain in advanced cancer.
CA1200501A (en)	1986-02-11	Nalbuphine - narcotic analgesic composition and method of producing analgesia
EP2574167B1 (en)	2015-12-16	Liquid nasal spray containing low-dose naltrexone
NO302736B1 (no)	1998-04-20	Farmasöytisk preparat omfattende tramadol og ibuprofen
US4282215A (en)	1981-08-04	Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
EP0514023B1 (en)	1996-03-20	Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
CA2476939A1 (en)	2003-08-28	Pharmaceutical combinations of cox-2 inhibitors and opiates
US4260629A (en)	1981-04-07	Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid
US4730007A (en)	1988-03-08	Novel analgesic compositions
CN116808038A (zh)	2023-09-29	阿片类物质和n-酰基乙醇胺的组合
US8148425B2 (en)	2012-04-03	Pharmaceutical composition containing phloroglucinol and paracetamol
EP2830605B1 (en)	2023-09-27	A combination medicament comprising phenylephrine and paracetamol
CN101778632B (zh)	2012-02-29	综合失调症的治疗或预防药
EP0024690B1 (en)	1983-07-20	Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4243673A (en)	1981-01-06	Analgesic compositions and methods of use
JPH0232020A (ja)	1990-02-01	モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
WO2018154495A1 (en)	2018-08-30	Pharmaceutical composition of oral solution of muscarinic antagonist
RU2083202C1 (ru)	1997-07-10	Препарат для анальгезии
WO2004026291A1 (en)	2004-04-01	Oral formulations of ibuprofen and tramadol, methods and preparation thereof